Verici Dx PLC on Tuesday announced the successful outcome of a clinical validation study of its Clarava test.

Shares in the Cardiff, Wales-based clinical diagnostics company were trading up 8.6% at 19.00 pence each in London on Tuesday midday.

Clarava is the company’s pre-transplant blood-based prognostic test for the risk of early acute kidney transplant rejection.

The study used a diverse population from 14 international transplant sites. The initial results suggest the Clarava diagnostic is ‘an effective tool to identify patients likely to experience a future transplant rejection’.

Verici said that data suggests Clarava is ‘a viable and compelling product for a broader patient population and commercialisation, as it has no directly competing products.’

Verici, whose laboratory is in Franklin, Tennessee, is extending enrolment in its clinical validation study for an additional six-month period to ‘support a statistically robust and clinically meaningful case for its adoption.’

Chief Executive Officer Sara Barrington said: ‘This new validating data demonstrates that Clarava can have a significant impact for transplant clinicians understanding of which patients could experience early acute rejection, pre-surgery.

‘As a result, clinicians can make better decisions in advance that can help drive better outcomes post-transplant.’

Copyright 2022 Alliance News Limited. All Rights Reserved.